Clinical Trials Browser

Phase 2 × Breast Carcinoma In Situ × 1 year × Clear all

NCT06184750 2026-03-19

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT05941520 2026-03-18

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT07443943 2026-03-02

AIMSS-RPS

Phase 2 Not yet recruiting

Breast Carcinoma In Situ

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Phase 2 Terminated

Breast Carcinoma In Situ, Breast Neoplasms

NCT03345420 2025-12-30

NOVEMBER

Phase 2 Completed

102 enrolled 12 charts

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT01245712 2025-12-17

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

Phase 2 Active not recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06008158 2025-12-10

Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca

Phase 2 Suspended

Breast Carcinoma In Situ

NCT06153836 2025-12-04

Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction

Phase 2 Recruiting

Breast Carcinoma In Situ

NCT06843681 2025-11-28

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study

Phase 2 Enrolling by invitation

Breast Carcinoma In Situ

NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Phase 2 Terminated

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

NCT06538389 2025-08-29

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Phase 2 Recruiting

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT06033092 2025-08-28

TOLERANT

Phase 2 Active not recruiting

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT07044310 2025-07-29

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Phase 2 Recruiting

Breast Carcinoma In Situ

NCT04290897 2025-07-15

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

Phase 2 Completed

Breast Carcinoma In Situ, Breast Neoplasms